Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped FDA released Octapharma from the pediatric post marketing requirement.

Conditions

Chronic Immune Thrombocytopenia

Interventions

BIOLOGICAL: Panzyga

Sponsor

Octapharma